Cargando…

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

SIMPLE SUMMARY: Patients with stage IIB-IV melanoma who have had surgery are recommended to receive systemic adjuvant therapy, intended to target the residual micro-metastatic disease and reduce the risk of melanoma relapse and death from melanoma. Multiple adjuvant therapy regimens have been tested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eljilany, Islam, Castellano, Ella, Tarhini, Ahmad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453009/ https://www.ncbi.nlm.nih.gov/pubmed/37627153 http://dx.doi.org/10.3390/cancers15164125

Ejemplares similares

Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab
por: Kobeissi, Iyad, et al.
Publicado: (2023)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review
por: Eljilany, Islam, et al.
Publicado: (2023)

An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)

D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review
por: Eljilany, Islam, et al.
Publicado: (2020)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma
por: Samlowski, Wolfram E., et al.
Publicado: (2017)

The use of immunotherapy in the treatment of melanoma
por: Achkar, Tala, et al.
Publicado: (2017)

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy
por: Khan, Shaheer, et al.
Publicado: (2022)

Neoadjuvant therapy of locally/regionally advanced melanoma
por: Khunger, Arjun, et al.
Publicado: (2019)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?
por: Indini, Alice, et al.
Publicado: (2021)

Considering adjuvant therapy for stage II melanoma
por: Poklepovic, Andrew S., et al.
Publicado: (2019)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
por: Testori, Alessandro A. E., et al.
Publicado: (2020)

Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
por: De Falco, Vincenzo, et al.
Publicado: (2021)

The Dilemma of Peri-Procedural Warfarin Management: A Narrative Review
por: Eljilany, Islam, et al.
Publicado: (2021)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
por: Stege, Henner, et al.
Publicado: (2021)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
por: Khaled, Mariam Lotfy, et al.
Publicado: (2023)

Recent advances in adjuvant therapy for patients with melanoma
por: Weber, Jeffrey
Publicado: (2018)

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
por: de Takats, P. G., et al.
Publicado: (1998)

Optimization: In-Depth Examination and Proposition
por: Phan, Huy Phuong, et al.
Publicado: (2019)

Enhancing Immunogenicity in Metastatic Melanoma: Adjuvant Therapies to Promote the Anti-Tumor Immune Response
por: Pelka, Sandra, et al.
Publicado: (2023)

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
por: Suarez-Kelly, Lorena P., et al.
Publicado: (2019)

Societal preferences for adjuvant melanoma health states: UK and Australia
por: Middleton, Mark R., et al.
Publicado: (2017)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
por: Saad, Mariam, et al.
Publicado: (2022)

Targeted Therapy; From Advanced Melanoma to the Adjuvant Setting
por: Ahn, Antonio, et al.
Publicado: (2013)

Extended Depth-of-Field Intraocular Lenses: An Update
por: Kanclerz, Piotr, et al.
Publicado: (2020)

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
por: Kirkwood, John M., et al.
Publicado: (2012)

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation
por: Mulder, E.E.A.P., et al.
Publicado: (2021)

Examining the Role of Familiarity in the Perception of Depth
por: Mischenko, Elizaveta, et al.
Publicado: (2020)

Adjuvant radiation therapy in metastatic lymph nodes from melanoma
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2011)

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
por: Ng, Gary, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pgi7sashr4p0ds1j3g2et1g7ur